Jacob Bell is a Senior Reporter at BioPharma Dive. He covers a diverse range of topics including pharmaceuticals, healthcare, and finance, while also exploring themes in technology and consumer tech. Jacob has been featured in various publications such as PharmaVoice, Yahoo Finance, and JD Supra.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Jacob Bell's coverage is heavily focused on the healthcare and pharmaceutical industries, with particular attention to biotechnology. His articles often incorporate press releases and data citations, indicating a preference for factual and industry-specific information.
Given his focus on private sector announcements, Jacob may be interested in pitches related to new product launches, significant investments or acquisitions within the healthcare and biotech sectors. Furthermore, he might be open to expert commentary from professionals well-versed in various aspects of biotechnology, pharmaceuticals, neurological diseases such as ALS research or gene therapy.
As there is no specific geographic focus mentioned for Jacob's coverage area, it would be beneficial to provide globally relevant insights pertaining to the topics covered.
This information evolves through artificial intelligence and human feedback. Improve this profile .
This story was originally published on BioPharma Dive . To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter
Founded by former MyoKardia executives, the startup has in mid- to late-stage testing three medicines licensed from the likes of Sanofi, Ionis and Bristol Myers Squibb.
The company made the announcement after a new round of research results bolstered the case for the experimental medicine, which may ultimately compete against Dupixent and Ebglyss.
All-American guard set for junior season at Vanderbilt
By: Jacob Bell
A twice-spurned therapy that’s been seen as one of the FDA’s more controversial recent rejections is getting a new chance following the resignation of former commissioner Marty Makary.
The French drugmaker has agreed to acquire an experimental tablet from Edgewise Therapeutics that some bullish analysts say could eventually hit peak sales of over $2 billion.
By: Jacob Bell
This story was originally published on BioPharma Dive . To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter
A possible alternative to “anti-CGRP” medications, the drug didn’t meet some analysts’ expectations in mid-stage testing but still convinced Lundbeck to pursue further development.
Acquiring Vega Therapeutics, an offshoot of “hub-and-spoke” biotech Star Therapeutics, would give Incyte a medicine that's in late-stage testing and designed to control bleeding.
In a wide-ranging interview, Abe Ceesay detailed how Rapport built an investor syndicate and why the company is confident it can join the ranks of successful, commercial-stage brain drugmakers.
